Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Pneumococcal infection

Pneumococcal infection

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Pneumococcal infection

10 trials tracked for Pneumococcal infection: 7 in phase 3 or 4 and 3 with published results. The most-cited published study has 63 citations.

10Trials tracked
7Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 1 Phase 3 6 Phase 2 1 Phase 1 1 Other / NA 1
  1. Phase 3 Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3) Completed · 63 cited
  2. Phase 3 Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) Completed · 5 cited
  3. Phase 3 Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) Completed · 4 cited
  4. Phase 4 Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902) Completed
  5. Phase 3 A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) Completed
  6. Phase 3 Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007) Completed
Show 4 more trials
  1. Phase 3 ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED) Completed
  2. Phase 2 A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine Completed
  3. Phase 1 Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002) Completed
  4. N/A Systems Biology of PNEUMOVAX®23 and PREVNAR 13® Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Early LAIV administration leads to 2.5-times increased odds of pneumococcal density at 14 days
Pediatrics RCT
Early LAIV administration leads to 2.5-times increased odds of pneumococcal density at 14 days Flu vaccine may increase bacteria levels in children and families
This randomized controlled trial of 405 families in the UK found that early live attenuated influenza vaccine (LAIV) significantly increased…
A new study shows that a specific flu vaccine can cause a temporary spike in bacteria that may spread to family members.
Oct 4, 2026